Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Healthy

In brief

This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

Key facts

Study ID

NCT04959812

Run by

University of Texas Southwestern Medical Center

People needed

46

Starts

2022-03-01

Expected to finish

2023-09-08

Last updated by the study team

2025-06-26

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18-45 years of age
• Healthy
• Non-obese (body mass index less than 30 kg/m2)
• Body mass greater than or equal to 65 kg
• Speak English

You may not qualify if…

• Subjects not in the defined age range
• Subjects who have cardiac, respiratory, neurological and/or metabolic illnesses
• Any known history of renal or hepatic insufficiency/disease
• Pregnancy or breast feeding
• Body mass less than 65 kg
• Current smokers, as well as individuals who regularly smoked within the past 3 years
• Subjects who cannot speak or read English
• Positive urine drug screen
• Currently taking pain modifying medication(s)

Where it is running

• Institute for Exercise and Environmental Medicine — Dallas, Texas, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.